EU Approves Takeda’s Injectable Entyvio for IBD
EU OK Follows FDA’s Recent Rejection Of The New Formulation
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
You may also be interested in...
Biosimilar vedolizumab rivals to Takeda’s Entyvio blockbuster will not materialize in the current decade, the Japanese originator has forecasted as part of a significantly extended IP landscape.
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.